Derrick Williams: Fostering collaboration and R&D quality
In an era when Member States are doing their utmost to limit national exposure in the EU budget, making the right choices has become more crucial than ever before to shaping Europe’s future.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Patents dancing in the spring
All the hard work I invested in 2012 to rescue the Eurozone with biotechnology has reaped a new reward in 2013, as the European Parliament and Council finally approved the European patent in December.
Serge Bernasconi: Getting regulation right for patients and innovation
The revision of the EU Medical Devices Directives (MDD) could not have come at a more critical moment. The recent PIP breast implant incident has made it crystal clear that healthcare actors must pull together to ensure similar cases of fraud never happen again.
Why biotech needs Europe and Europe needs biotech
It’s getting a little boring listening to conversations about the 2014-2020 budget. As citizens, we’re subjected to endless national bickering and point-scoring as national leaders look to secure their own positions through sounding tough on Europe’, as if the EU was a strange alien beast designed to steal their money and straighten all their bananas.
Nigel Sheail: Partnering for innovative healthcare solutions
Partnering and even open innovation is becoming increasingly important for our industry in a world where health systems are undergoing profound transformations.
When scientists have to strike at their own
We all read with dismay but not a huge amount of surprise the October paper from French researchers led by Gilles-Eric Séralini on the two-year rat-feeding study looking at the effects of glyphosate-treated GM maize.
Regina Revilla/Emilio Munoz: The Importance of innovation in weak economics
Since the beginning of the year, there have been numerous government initiatives in the most advanced countries to implement and strengthen policies to support biotechnology.
When science makes you smile
Hello readers! You know, when you view the biotechnology landscape from a Brussels perspective, you can very easily get stuck looking at the bad bits meddling politicians, poor science reporting, insane funding decisions. Goodness knows I have had to solve the euro crisis already this year, and most months I have something or other to moan about.
Andrea Rappagliosi: Challenges and answers: HTA in the economic crisis
During the last thirty years, healthcare expenditure has been growing much more rapidly than GDP in OECD countries, causing increasing concerns about the long-term sustainability of current trends. As we have seen with the global impact of the financial crisis, economic realities are moving faster than political ones.
Fixing Europe (again)
Well ladies and gentlemen of the biotechnology community, welcome back after the silly season. I hope you had a nice one, whether it was in the sunny bit, the rainy bit or the bits that were on fire. As usual, summer in Europe was quiet. I see we still have a Eurozone, which is nice, and shows that the revolutionary, biotech-driven solution I came up with earlier in the year is still working.